Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × Gemcitabine × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 151 Triple Negative Breast Neoplasms 45 Neoplasm Metastasis 19 Pancreatic Neoplasms 15 Carcinoma, Non-Small-Cell Lung 14 Ovarian Neoplasms 10 Colorectal Neoplasms 8 Small Cell Lung Carcinoma 7 Sarcoma 7 Prostatic Neoplasms 7 Neoplasms 7 Lung Neoplasms 7 Breast Neoplasms, Male 7 Colonic Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Lymphoma, Non-Hodgkin 5 Squamous Cell Carcinoma of Head and Neck 4 Head and Neck Neoplasms 4 Cholangiocarcinoma 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Melanoma 3 Kidney Neoplasms 3 Fallopian Tube Neoplasms 3 Uterine Cervical Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Osteosarcoma 2 Multiple Myeloma 2 Hodgkin Disease 2

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡